rss
BMJ Case Reports 2009; doi:10.1136/bcr.09.2008.0845
  • Unexpected outcome (positive or negative) including adverse drug reactions

New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis

  1. Christina Jost1,
  2. Josef Hermann1,
  3. Laila El-Shabrawi Caelen2,
  4. Winfried Graninger1
  1. 1
    Medical University Hospital Graz, Division of Rheumatology, Auenbruggerplatz 15, Graz, 8036, Austria
  2. 2
    University Hospital Graz, Department for Dermatology and Venerology, Auenbruggerplatz 8, Graz, 8036, Austria
  1. Christina Jost, christina.jost{at}klinikum-graz.at
  • Published 6 March 2009

Summary

Administration of abatacept is a new treatment modality for rheumatoid arthritis (RA). We describe a patient in whom psoriasiform skin lesions developed 4 months after the initiation of abatacept therapy for longstanding, rheumatoid factor positive RA. Histological findings were consistent with psoriasis. The skin lesions subsided after discontinuation of abatacept and reappeared after re-exposure to the drug, suggesting a causal connection between abatacept and the development of psoriasis.

Footnotes

  • Competing interests: none.

  • Patient consent: Patient/guardian consent was obtained for publication.

This Article

  1. Summary
  2. Full text

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog